AllAnalyst Report
logoArgusNovember 18, 2020

Biogen Inc.: Maintaining HOLD as competition grows in the MS market

Symbols
BIIB
Sector(s)
Healthcare
Rating
Current Price
$208.90
Price Target
Earnings Estimate
Summary

Biogen is a biotech company that researches, develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases worldwide. The company is the market leader in drugs that treat multiple sclerosis and has recently introduced the first approved treatment for spinal muscular atrophy. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia and rheumatoid arthritis. Current research continues on multiple sclerosis and has expanded to include neuroimmunology, Alzheimer's d

Upgrade to begin using premium research reports and get so much more.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Upgrade

Analyst Profile

Jasper Hellweg

Associate Analyst: Growth Pharmaceutical, Medical Technology & Financial Technology
At Argus Research, Jasper covers the Growth Pharmaceutical, Medical Technology, and Financial Technology companies. He received his undergraduate degree from Boston University, graduating cum laude with a Bachelor of Science degree in Business Administration with concentrations in Entrepreneurship and Marketing. Prior to joining Argus, Jasper worked in a variety of industries, ranging from investment tradeshow management to musical instrument manufacturing. He started his career at Argus in the Research department and has since widened his scope to also include becoming a regular contributor for the Market Movers and Market Digest publications, the Vickers Weekly Insider Report and Argus' bespoke research on IPOs.